ChemDiv and Berlex Announce Collaboration
News Mar 13, 2006
ChemDiv, Inc. has announced that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The partners will work on the discovery of potential new lead compounds against several selected GPCR targets.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies.
"We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc.
"ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE